Axe Compute Inc. has completed the sale of its wholly-owned subsidiary Helomics Corporation to DataMEDS AI, Inc. The transaction, executed on September 11, 2026, and announced on September 15, 2026, marks the final step in Axe Compute’s strategic shift away from its former identity as Predictive Oncology Inc. The company is now transitioning to a pure-play neocloud GPU-as-a-Service business.
Under the terms of the Stock Purchase Agreement, DataMEDS acquired Helomics in exchange for a combination of equity and debt instruments. The purchase price consists of 636,328 shares of DataMEDS common stock, representing 19.99% of the outstanding shares immediately prior to the closing, and a convertible promissory note with a principal amount of $1,363,672. The conversion price for the note is set at $1.00 per share.
The securities issued in the transaction are subject to a 12-month lock-up period, during which Axe Compute may not transfer them except to affiliates or with DataMEDS’ prior written consent. The agreement also includes customary representations, warranties, and registration rights for the Company. Additionally, Axe Compute agreed to pay the remaining base rent obligations under two leases for the premises occupied by Helomics in Pittsburgh, Pennsylvania, through the expiration of the current lease terms.
Helomics is a Pittsburgh-based functional precision medicine oncology platform that utilizes artificial intelligence to analyze real-world tumor data for drug discovery and cancer treatment decisions. Following the sale, Axe Compute retains a stake in DataMEDS, positioning the company to benefit from the future growth of the acquired business.
